Aims Coupling factor 6 (CF6) induces hypertension by attenuating the endothelial generation of prostacyclin. However, intracellular signalling of CF6 in the resistance arteriole vascular smooth muscle cells (VSMCs) that are directly related to vasoconstriction has not been determined. Here we investigated the direct effect of exogenous CF6 on Ca 2þ signalling in cultured VSMCs and the in vivo role of endogenous CF6 in the genesis of hypertension using CF6 transgenic (TG) mice. Methods and results CF6 induced a monophasic increase in the intracellular free Ca 2þ concentration ([Ca 2þ ] i ) through nifedipine-sensitive Ca 2þ channels in A7r5 cells, a cell line of VSMCs, and enhanced the angiotensin II-induced spike phase of [Ca 2þ ] i to a greater degree in VSMCs derived from spontaneously hypertensive rats (SHRs). In the mesenteric arterioles obtained from CF6-TG mice that manifested hypertension, angiotensin II-induced vasoconstriction was enhanced, compared with wild-type mice, and its enhancement was abolished by an anti-CF6 antibody. Pre-treatment with PP1, a tyrosine kinase c-Src inhibitor, blocked CF6-induced increase in Ca 2þ signalling in VSMCs and vasoconstriction in TG mice. The receptor of CF6 was F 1 motor of adenosine triphosphate (ATP) synthase with a higher affinity in SHRs. CF6 decreased intracellular pH via activation of ATPase activity and led to c-Src activation to a greater degree in SHR-derived VSMCs. Conclusion CF6 causes hypertension by directly enhancing Ca 2þ signalling in VSMCs and vasoconstriction in the mesenteric arteriolar network via c-Src activation.
Introduction
Mitochondrial adenosine triphosphate (ATP) synthase is a supermolecule composed of at least 14 subunits that have a constant stoichiometry, six of which construct the catalytic site of ATP synthase known as F 1 and eight of which construct an energy transduction part known as F o .
1,2 Coupling factor 6 (CF6) is a component of F o and is reported to be essential for energy transduction. 3 We recently identified a novel function for CF6 while investigating the suppression mechanism of prostacyclin generation in spontaneously hypertensive rats (SHRs). CF6 suppresses the synthesis of prostacyclin via inhibition of cytosolic phospholipase A 2 , 4 and injected CF6 consistently induces an increase in arterial blood pressure. 5 Recently, we showed that the level of circulating CF6 is elevated in SHRs, and the neutralization of its peptide with a specific antibody decreases arterial blood pressure to a greater degree in SHRs than in Wistar Kyoto rats (WKY). 5 CF6 is released from the surface of vascular endothelial cells, and its release is stimulated by tumour necrosis factor-a and shear stress through activation of nuclear factor-kB signalling. [6] [7] [8] More recently, we showed that plasma membrane-bound ATP synthase in the vascular endothelial cells functions as a receptor for CF6 and may play an important role in the elevation of blood pressure and atherogenesis by increasing the concentration of intracellular proton, acidosis. 9, 10 Although biological functions of CF6 in the vascular endothelial cells were well characterized, the intracellular signalling and the in vivo role of CF6 in the resistance arterioles that are directly related to hypertension have not been determined. ATP synthase was recently reported to be ubiquitously distributed to the plasma membrane as well as the mitochondria in various types of cells. 9, [11] [12] [13] Therefore, it is reasonable to presume that plasma membrane-bound ATP synthase, which was recently identified as the receptor of CF6, may be present in the resistance arteriole vascular smooth muscle cells (VSMCs) and functions as a novel target for the effects of CF6. The tyrosine kinase c-Src is a key enzyme to regulate a number of downstream effectors related to vasoconstriction, 14 and intracellular acidosis, which is relevant to a process of the intracellular signalling of CF6, induces activation of c-Src, 15 suggesting a linkage of CF6 to c-Src. The activation of c-Src enhances the L-type voltage-gated Ca 2þ current 16, 17 and the Ca 2þ release from intracellular stores in response to angiotensin II (AngII) via tyrosine phosphorylation of Ca 2þ channel and phospholipase C g-1.
18 Therefore, we investigated the direct effect of exogenous CF6 on Ca 2þ signalling in cultured VSMCs and the in vivo role of endogenous CF6 in the genesis of hypertension using CF6-over-expressing transgenic (TG) mice. Here, we report that CF6 causes hypertension by directly enhancing Ca 2þ signalling via c-Src activation in the resistance arteriole VSMCs.
Materials and methods

Construction of vector and generation of transgenic mice
The study protocol was approved by the Animal Committee of the Hirosaki University. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . A gene for the N-terminal portion of human calcitonin (Met1-Arg84) was fused to a gene for the mature ATP synthase CF6 (Asn33-Ala108). The fused gene was subcloned into pNE plasmid, in which the b-globin promoter of the pdKCR-dhfr plasmid 19 was replaced by the human elongation factor 1 alpha promoter. The resultant recombinant plasmid was digested with PvuII and Aor51HI to generate 2.8 kb of DNA fragment consisting of the human elongation factor 1 alpha promoter, human calcitonin/CF6-fused gene, and SV40 polyA additional sequence. The DNA fragment was then microinjected into the pronuclei of single cell fertilized mouse embryos to generate TG mice. Using COS cells, it was confirmed that mature human CF6 (Asn31-Ala108) was released outside the cells after expression of fused gene of N-terminal portion of human calcitonin and human mature CF6. Mice were backcrossed more than 12 generations into C57BL/6J (Japan Cler, Tokyo). Littermates not expressing the transgene were used as controls. CF6-TG mice and wild-type (WT) mice C57BL/6J were maintained with standard rat food and free access to water.
Vasoconstriction of isolated mesenteric arterioles
Isolated mesenteric resistance arteries (60-160 mm in internal diameter, second or third branch), which were kept in ice-cold phosphate-buffered saline (PBS), were transferred for cannulation into a Lucite vessel chamber containing albumin-PBS (pH 7.4) equilibrated with room air at ambient temperature. Both ends of the vessel were cannulated with micropipettes filled with albumin-PBS and securely tied with 11-0 ophthalmic sutures (Alcon). The vessel was then transferred to the stage of an inverted microscope (IX70, Olympus) coupled to a CCD camera (CS330, Olympus) and a video micrometer (Microcirculation Research Institute, Texas A&M University Health Science Center). The micropipettes were connected to an independent pressure reservoir system, and intraluminal pressures were measured through side arms of the two reservoir lines by low-volume-displacement strain-gauge transducers. The isolated vessels were pressurized without flow by setting both reservoirs at the same hydrostatic level (60 cm H 2 O). Internal diameters of the vessel were measured throughout the experiment by video microscopic techniques. 20 Each cannulated vessel was bathed in albumin-PBS and equilibrated at room air, and the temperature was maintained at 36-378C. The vessel was set to its in situ length and allowed to develop basal tone. After a stabilization period of 60 min, increasing doses of AngII (10 215 -10 26 M) were administered to the vessel bath. To investigate the effects of selective c-Src inhibitor PP1 (Biomol International, L.P., Plymouth Meeting, PA, USA) at 50 mM and anti-CF6 antibody (dilution of 1:1000), the effects of each dose of AngII on the mesenteric arteriolar diameter were observed before and after treatment with PP1 and anti-CF6 antibody, which were added to the vessel bath 30 min before the administration of AngII and was present throughout the study. Using different preparations, acetylcholine (10
28
-10
25 M)-induced changes in the mesenteric arteriolar diameter were observed after pre-constriction with 40 mM KCl. The vasoconstrictor effect of CF6 was expressed as per cent changes from the baseline diameter. The vasodilator changes were normalized to the maximum dilation in the presence of sodium nitroprusside (10 24 M) and expressed as a percentage of maximum dilation.
Culture of vascular smooth muscle cells
Mesenteric arteriole VSMCs obtained from male SHRs and WKY at the ages of 16 weeks were cultured as reported previously. 21 Briefly, the mesenteric arteries and their small vascular networks were minced with scissors, incubated in digestion enzymes, and then VSMCs were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 mg/mL streptomycin, and 100 U/mL penicillin (complete DMEM) at 378C under 5% CO 2 -95% air. Each cell line was characterized by immunocytochemical study of a-smooth muscle cell actin. The mesenteric VSMCs at passages 1-3 were used. A7r5 cells, a cell line of rat aortic VSMCs expressing voltage-gated Ca 2þ channel, were purchased from American Type Culture Collection and cultured in complete DMEM.
Procedures for radioimmunoassay (RIA) of CF6
RIA for CF6 was performed as reported previously. 5 Briefly, the standard recombinant CF6 or the unknown sample was incubated with anti-CF6 antiserum diluent for 12 h, and then the tracer solution (18 000-20 000 cpm) was added. After incubation for 24 h, radioactivity of the precipitate was measured with a gamma counter.
Determination of CF6 gene expression
CF6 gene expression was analysed by reverse transcriptase (RT)-polymerase chain reaction (PCR) as reported previously. 5 The cDNA was prepared from mRNA and amplified in a PCR reaction mixture by 25 cycles. Oligonucleotide primers designed against the N-terminal region of CF6 were forward primer 5 0 -TGTC CTTCGGTCAGCAGTCTC-3 0 and reverse primer 5 0 -AACTTATCCATC TCTCCTTTA-3 0 . The PCR products were separated on agarose gel and photographed under ultraviolet irradiation at 320 nm. The relative quantity of cDNA was assessed by the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase. The linear amplification of each primer pair occurred between 20 and 30 cycles. All RT-PCR studies were performed in duplicate in all specimens.
Measurement of intracellular free calcium concentration
Intracellular Ca 2þ concentration was determined with the Ca 2þ -sensitive dye fura-2 after the cells were incubated for 24 h in serumfree media. Quiescent VSMC monolayers on plastic Aclar cover slips were loaded with 5 mM fura-2 in serum-free DMEM for 20 min at 378C. The cover slips were mounted in a quartz cuvette with 2 mL Krebs-Henseleit HEPES, pH 7.4, maintained at 378C with constant stirring. Intracellular Ca 2þ concentration was determined by measuring fluorescence with a spectrophotometer at 340 and 380 nm excitation and 510 nm emission. 21 In experiments in which BAPTA, a high affinity Ca 2þ chelator, was used, 30 mM BAPTA acetoxymethylester was added and coincubated with fura-2 in DMEM exactly as described earlier. In the Ca 2þ channel study, A7r5 cells, a kind of the cell line expressing voltage-gated Ca 2þ channel constitutively, were used instead of primary cultured VSMCs, as voltage-gated Ca 2þ channels are easily lost during primary culture.
Flow cytometry analysis
Cell surface CF6 and the b-subunit of ATP synthase were analysed using a FACScan. 6 VSMCs were trypsinized, washed, and reacted with saturating concentrations of anti-CF6 and anti-b-subunit of ATP synthase (the receptor for CF6) antibodies (both dilution of 1:1000) in PBS containing 1% bovine serum albumin for 30 min on ice. After washing three times with PBS, they were stained with fluorescein isothiocyanate-conjugated goat anti-rabbit immunoglobulin (IgG) for 30 min and then analysed in a FACScan.
Binding assay for CF6
A CF6 binding study was performed using VSMCs on 24-well plate, as described previously. 9 Briefly, each well was incubated in serumfree DMEM containing 125 I-CF6 with unlabelled CF6 at 378C under 5% CO 2 . After 30 min, bound radioligand was separated by rapidly washing and counted in a gamma counter. Non-specific binding was assessed by incubating the cells in the presence of 10 26 M unlabelled CF6 and found to be 20 + 5% of the total binding.
Assays for adenosine triphosphate synthase activity
ATPase activity was assayed by a spectrophotometric procedure, as described previously. 9, 22 Briefly, ATPase activity was monitored spectrophotometrically at 340 nm by coupling the production of adenosine diphosphate (ADP) with the oxidation of nicotinamide adenine dinucleotide via the pyruvate kinase and lactate dehydrogenase reactions.
Intracellular pH measurement
Intracellular pH was measured using BCECF-AM after the cells were incubated for 24 h in serum-free medium, as reported previously. 9 Quiescent VSMCs were incubated in PBS containing BCECF-AM (1 mg/mL) for 15 min at 378C. Excess dye was removed by centrifugation, and the cells were suspended in nominally HCO 3 2 -free KHH containing 0.2% fatty acid-free bovine serum albumin. The suspension was transferred to a cuvette that was placed in the temperature-controlled chamber of a Shimazu 5000 luminescence spectrophotometer, maintained at 378C. Using a dual excitation fast filter accessory, the sample was excited at 495 and 440 nm successively, and the fluorescence emission was measured at 535 nm. The ratio of the fluorescence intensity measured using the two excitation wavelengths (495/440 nm) provides a quantitative measure of pH. Calibration with the K þ /H þ ionophore, nigericin, at 5 mg/ mL was performed as described previously.
Immunoprecipitation and western blot analysis
c-Src activation was measured by western blot analysis as described previously. 9 The whole cell lysate after 15 min exposure to CF6 at 10 27 M was subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories). After blocking for 1 h, the membranes were incubated with the primary antibodies for b-subunit of ATP synthase, c-Src, or phosphotyrosine, followed by the secondary antibody. In the immunoprecipitation study, the plasma membrane fraction obtained from SHRs was solubilized and co-incubated with CF6 in ice-cold lysis buffer containing protease inhibitor. After 1 h incubation with anti-CF6 antibody or b-subunit antibody, the proteins were immunoprecipitated by protein A/G PLUS-agarose beads and finally stained with the anti-CF6 antibody. The protein bands were detected by ECL plus detection system (Amersham Pharmacia Biotech). Densitometric analysis was performed with NIH image software.
Measurement of blood pressure
Systolic arterial blood pressure at baseline was measured by the tail-cuff method under consciousness and by direct arterial cannulation in mice anaesthetized with 75 mg/kg of ketamine hydrochloride and 15 mg/kg of xylazine hydrochloride, as reported previously. 5 Briefly, a polyethylene catheter filled with heparinized saline solution (20 U heparin/mL) was inserted via the left carotid artery. The carotid catheter was connected to a pressure transducer coupled to a polygraph.
Statistics
All data are shown as mean+1 SEM. An unpaired t-test for comparison of two variables and one-way and two-way analysis of variance (ANOVA) for multiple comparisons followed by Bonferroni's test were used for statistical analysis. Mean values were considered significantly different when P , 0.05.
Results
Characterization of transgenic mice on standard diet
In CF6-overexpressing TG mice, the fused gene of N-terminal portion of human calcitonin and human CF6 was expressed in a widespread distribution, especially in the organs where endogenous CF6 was expressed to a greater degree ( Figure 1A) . The gene expression of CF6 mRNA was upregulated by two-fold in overall tissues, including the mesenteric arterioles, concomitantly with a two-fold increase in the protein expression. The level of circulating CF6 was slightly elevated in TG mice compared with WT, but the difference was not significant. During development, there was no difference in the growth rate, body weight, and food intake between WT and TG mice. Systolic arterial blood pressure at baseline was elevated in one line of TG mice compared with WT at the age of 15-20 weeks (120 + 5 vs. 110 + 3 mmHg by tail-cuff method, P , 0.05; 115 + 4 vs. 104 + 3 mmHg by direct arterial method, P , 0.05), but not in another line (105 + 4 vs. 100 + 3 mmHg, P ¼ 0.07). Figure 1B shows the effect of AngII on the diameter of the mesenteric arterioles from WT and TG mice. The addition of AngII to the vessel bath produced a transient and rapid vasoconstriction within seconds, reaching the maximal increase within 30 s, and persisted. At doses of .10 211 M, AngII caused a significant and dose-dependent vasoconstriction, and the diameter change from the baseline was greater in TG mice than in WT mice (P , 0.05, two-way ANOVA). Pre-treatment with PP1 and anti-CF6 antibody suppressed AngII-induced vasoconstriction to a greater degree in TG mice compared with WT, thereby eliminating the difference between TG and WT. The greater vasoconstrictor response to AngII was completely restored in TG mice after replacing the bath solution with fresh albumin-PBS. As shown in Figure 1C , the dilation response to acetylcholine was similar between WT and TG mice. The resting diameter at 60 cm H 2 O was similar between the TG and WT vessels (119 + 6 vs. 113 + 6 mm, P ¼ ns).
Effect of endogenous CF6 on vasoconstriction of mesenteric arterioles in transgenic mice
Effect of exogenous CF6 on Ca
21 signalling in cultured vascular smooth muscle cells Figure 2A- Figure 2C , the CF6-induced increase in peak [Ca 2þ ] i in response to AngII at 10 27 M was greater in SHRs than in WKY (412 + 26 vs. 162 + 14 nM, P , 0.05).
3.4 Enhanced intracellular signalling of CF6 in spontaneously hypertensive rat mesenteric vascular smooth muscle cells 3.4 .1 Interaction between CF6 and cell surface adenosine triphosphate synthase Fluorescence-assisted flow cytometry experiments in intact cells confirmed the cell-surface localization of the a-and b-subunits in SHR mesenteric VSMCs. The selectivity of the response to the a-and b-subunit antibodies was clearly shown by substantially low signal obtained with isotypic IgG. After pre-incubating the cells with CF6, the immunoreactivity for the anti-CF6 antibody was enhanced at the surface of VSMCs ( Figure 3A) , suggesting that the binding site of CF6 is present on the cell surface. Incubation of VSMCs with an excess of free CF6 reduced the immunoreactivity for the b-subunit antibody by 50% ( Figure 3C ), but did not affect that for the a-subunit antibody ( Figure 3B) . Identical results were observed in separate experiments in WKY-derived VSMCs. This confirmed the cell-surface interaction of free CF6 with the b-subunit of ATP synthase. Immunoprecipitation analysis directly showed the binding of CF6 and b-subunit in vitro ( Figure 3D) . One band for protein immunoprecipitated with anti-b-subunit antibody (lane 2) was identical to that for CF6 (lane 1). Figure 4E shows competitive displacement analysis of the receptor of CF6. A significant displacement of radioligand was observed at 10 210 and 10 29 M unlabelled CF6 in SHR and WKY, respectively, and the maximum displacement was seen at 10 27 M in both strains. As estimated by the method of Cheng and Prusoff, the Kd of CF6 to the b-subunit of ATP synthase was lower in SHR than in WKY (3.6 + 0.3 vs. 9.6 + 0.3 nM, P , 0.05), despite no difference in B max . As shown in Figure 3F , the b-subunit antibody suppressed the binding of 125 I-labelled CF6 by 38.0 + 4.0% in SHRs (P , 0.05). In contrast, the a-subunit antibody did not affect the binding of 125 I-labelled CF6. ADP at 10 27 M suppressed the binding of CF6 by 78.5 + 5.7% (P , 0.05). Neither ATP at 10 27 M nor efrapeptin at 10 25 M influenced the binding of 125 I-CF6. Similar results were observed in WKY.
Effect of CF6 on adenosine triphosphate synthase activity
As shown in Figure 4 , the hydrolysis activity of ATP to ADP on the surface of VSMCs was verified by using a coupled enzymatic assay, in which the production of ADP is linked to the oxidation of NADH via pyruvate kinase and lactate dehydrogenase. ATPase activity was similar between SHR and WKY at baseline, but was greater in SHRs compared with WKY in the presence of CF6 at 10 27 M (58.1 + 7.6 vs. 34.6 + 8.4%, P , 0.05). Pre-treatment with efrapeptin at 
10
25 M blocked the CF6-induced increase in ATPase activity in both strains without affecting its activity at baseline. Figure 5A -D illustrates representative tracings of changes in intracellular pH after administration of CF6 in SHR-derived VSMCs. CF6 at 10 27 M decreased intracellular pH within seconds, reaching the maximal decrease within 2 min and returning to baseline after several minutes ( Figure 5A ). Pre-treatment with efrapeptin at 10 25 M abolished the reduction of intracellular pH in response to CF6 at 10 27 M ( Figure 5B ). PP1 at 50 mM did not affect the decrease in intracellular pH in response to CF6 at 10 27 M ( Figure 5C ). Intracellular pH at baseline was 7.20 + 0.04 and 7.21 + 0.03 in SHR-and WKY-derived VSMCs, respectively. The maximum decrease in intracellular pH in response to CF6 at 10 27 M was greater in SHRs than in WKY (0.26 + 0.03 vs. 0.13 + 0.02, P , 0.05) ( Figure 5D ). Figure 5E shows representative bands for CF6-induced phosphorylation of c-Src in VSMCs. CF6 at 10 27 M induced phosphorylation of c-Src at 10 min that was two-fold greater in SHRs than in WKY (P , 0.05) ( Figure 5F ). Pretreatment with efrapeptine at 10 25 M blocked phosphorylation of c-Src concomitantly with blockade of intracellular acidosis.
Effect of CF6 on intracellular pH and c-Src
Discussion
The major findings of the present study were that CF6 enhanced Ca 2þ influx through nifedipine-sensitive Ca 2þ channels and AngII-induced Ca 2þ mobilization from intracellular Ca 2þ store via c-Src activation in cultured VSMCs and that CF6 induced hyperresponsiveness to AngII in mesenteric arterioles.
Role of endogenous CF6 in vasoconstriction of resistance arterioles in transgenic mice
As CF6 could elicit its novel function only outside the cells, the introduced gene product was designed to be released outside by constructing the fusion of N-terminal portion of human carcitonin (Met1-Arg84) at the upstream of mature CF6. It was verified by a direct finding of the COS cells that CF6 (Asn33-Ala108) was detected in the culture media after transfection of the fusion gene and by an indirect finding that mitochondrial dysfunction due to the misleading of CF6 to the mitochondria was lacking in TG mice. The TG mice manifested a two-fold increase in CF6 mRNA expression in the overall tissues including mesenteric arterioles and a slight elevation of circulating CF6. Thus, it appears that the high level of local tissue CF6 such as that in the resistance arterioles induced vasoconstriction in an autacoid rather than a hormone fashion. In the resistance arterioles obtained from the TG mice, AngII-induced vasoconstriction was enhanced and the dilation response to acetylcholine was maintained, suggesting that hyperresponsiveness to AngII in the TG mice is not secondary to endothelial dysfunction but related to a direct effect of CF6 on VSMCs. Using a blockade agent of c-Src, we further clarified that CF6 enhanced the AngII-induced constriction of the resistance arterioles through c-Src activation ex vivo. In contrast, arterial blood pressure as its in vivo effect, measured by the tail-cuff method under consciousness, was elevated by 10 mmHg in one line of the TG mice as expected, but elevated by 5 mmHg and not significant in another line. This disparity seems to depend on the difference of the compensatory action at the chronic stage. Of note, CF6 evoked vasoconstriction by a direct effect on the resistance arteriole VSMCs in an autocrine or paracrine fashion, independent of its attenuating effect on the endothelial prostacyclin production. As the activation of ATP synthase is accompanied by a flux of proton through F o , we measured intracellular pH using the hydrogen-sensitive dye BCECF and characterized the postreceptor signalling of CF6 in VSMCs. As expected, intracellular pH was decreased within seconds after administration of CF6 and the cellular acidosis lasted for several minutes. Because c-Src was shown to become activated on acidification, 15 we investigated the effect of efrapeptin, an inhibitor of ATPase, on c-Src activation in response to CF6. Efrapeptin dampened the decrease in intracellular pH and the increase in c-Src phosphorylation in response to CF6. Taken together, our data suggest that CF6 decreased intracellular pH via upregulation of ATPase activity and led to activation of c-Src. Importantly, CF6-induced c-Src activation was enhanced in SHRs likely due to the higher affinity of the receptor and the greater degree of ATPase activation and acidification found in SHRs compared with WKY. Thus, intracellular signalling of CF6 from binding to its receptor through to the increase in [Ca 2þ ] i was enhanced in the resistance arteriole VSMCs obtained from SHRs, suggesting a causal association with the genesis of hypertension.
Implications of CF6 in cardiovascular disorders
In clinical settings, we previously showed that the level of circulating CF6 was elevated in patients with essential hypertension and modulated by salt intake presumably via reactive oxygen species. 23 We further showed that the plasma level of CF6 is related to the development of ischaemic heart disease complicated with end-stage renal disease. 24 Li et al. 25 showed that the plasma level of CF6 was elevated in patients with type 2 diabetes mellitus and negatively correlated with that of prostacyclin. The same group further showed that the plasma level of CF6 was elevated in patients with coronary heart disease and acute myocardial infarction and was concerned with the formation of their pathophysiology. 26, 27 Being consistent with the clinical findings, the cell study revealed that CF6 changes the gene expression profile to be proatherogenic. 10 In conclusion, results of the current study show that CF6 enhances Ca 2þ signalling and vasoconstriction in resistance arteriole smooth muscle cells and in the mesenteric arteriolar network via c-Src activation and that calcium concentration and c-Src activation were increased in a CF6-overexpressing model. CF6 appears to play an important role in the genesis of hypertension, making CF6 a target molecule for novel therapeutic strategies in the treatment of cardiovascular disorders.
